ClinicalTrials.gg
Enrolling by invitationNCT06745011PromparkUpdated Jan 8, 2025

Prodromal Model of Parkinson's Disease Confined to The Peripheral Nervous System

An observational study in Polyneuropathy, Alpha-Synucleinopathy and Lewy Body Disease, sponsored by University of Aarhus. Enrolling by invitation at 1 site in Denmark. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-01-08.

Sponsored by University of Aarhus · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
100
Ages
18 Years to 85 Years
Sex
All
01

Study summary

Description of a method to detect Parkinson's disease or Parkinson's-like disease at an early stage (Prodromal Parkinson's Disease) where damage is still confined to the peripheral nervous system damage. Simultaneous collection of biological material to establish a biobank for use as prognostic biomarkers for the development of Parkinson's disease and other neurodegenerative diseases in which pathological alpha-synuclein deposits accumulate.

Read the detailed description

Primary aim (baseline):

To assess the prevalence of isolated REM Sleep Behavior Disorder (iRBD) or REM sleep without atonia (RSWA) in patients with idiopathic polyneuropathy with as to without abnormal cardiac 123I-metaiodobenzylguanidine (MIBG) scintigraphy (assessment of cardiac sympathetic innervation)

Secondary aim (baseline):

To assess the prevalence of Parkinson's Disease (PD), Dementia with Lewy bodies (DLB) and Multiple System Atrophy (MSA) in patients with idiopathic polyneuropathy.

Hypothesis (baseline):

iRBD is more prevalent in patients known with idiopathic polyneuropathy and abnormal sympathetic innervation of the heart (assessed by cardiac 123I-MIBG scintigraphy) as compared to normal cardiac sympathetic innervation.

Primary aim (5-follow-up):

To assess whether patients with idiopathic polyneuropathy develop RSWA, iRBD, PD, DLB or MSA over a periode of five years.

Hypothesis (5-follow-up):

Patients known with idiopathic polyneuropathy and abnormal sympathetic innervation of the heart (assessed by cardiac 123I-MIBG scintigraphy) will convert to RSWA, iRBD, PD, DLB or MSA more often than those with normal cardiac sympathetic innervation.

Methods:

Clinical evaluation in combination with questionnaires, multi-modal imaging methods and polysomnography.

(Assessment of neuropathy: Neuropathy Impairment Score - Lower Leg (NIS-LL), Utah Early Neurological Scale (UENS), Kumamoto Neurological Scale and autonomic function test including Tilt table Test, Valsalva Maneuver, Deep Breathing Test, The Quantitative sensory axon reflex test (QSART). Cognition: The Montreal Cognitive Assessment (MoCA), Trail making Test B (TMT-B). Motor function: MDS-Unified Parkinson's Disease Rating Scale part III (MDS-UPDRS-III). Multi-modal imaging: cardiac 123I-MIBG scintigraphy, PE2I-PET-CT, MR-neuromelanin. Sleep: REM Sleep Behavior Disorder Screening Questionnaire (RBDSQ), one-night video polysomnography (PSG).)

Statistics:

The researchers expect to enroll 100 participants with idiopathic polyneuropathy and orthostatic hypotension or abnormal 24-hour blood pressure measurement (non-nocturnal blood pressure dip) who have undergone cardiac 123I-MIBG scintigraphy. Based on preliminary results, the investigators expect that 1/3 (30 participants) will have abnormal cardiac MIBG scintigraphy (cases; suggested to have prodromal PD or DLB) and 2/3 (70 participants) with normal MIBG scintigraphy (controls). The prevalence of iRBD detected by video-PSG is assumed to be 5% in participants with normal cardiac MIBG scintigraphy and 35% in participants with abnormal MIBG scintigraphy. To achieve a power of 88%, 81 participants have to be included (54 with normal and 27 with abnormal cardiac MIBG scintigraphy). Power calculation was based on Fisher's exact-test. Fisher's exact test was used because of an expected small number of participants with video PSG-detected iRBD.

Biobank:

Simultaneously collection of body tissue/fluids: skin, blood, cerebrospinal fluid and faeces. Analysis of the levels of phosphorylated tau, total-tau and amyloid beta in cerebrospinal fluid is performed at baseline.

02

Conditions studied

  • Polyneuropathy
  • Alpha-Synucleinopathy
  • Lewy Body Disease
  • Parkinson Disease (PD)
  • Lewy Body Dementia (LBD)
  • Multiple System Atrophy
  • Autonomic Failure
  • Cardiac Imaging
  • Rapid Eye Movement Sleep Behavior Disorder
  • REM Sleep Behavior Disorder (iRBD)
  • REM Behavior Disorder

Keywords

  • Isolated Rapid Eye Movement Sleep Behavior Disorder
  • REM Sleep Behavior Disorder
  • Polyneuropathy
  • Idiopathic Polyneuropathy
  • Cardiac MIBG Scintigraphy
  • Prodromal Lewy Body Disease
  • Lewy Body Disease
  • Alpha-synucleinopathy
03

In context

Polyneuropathies

133 studies on the registry are indexed under Polyneuropathies; 33 are open to participants now.

This study's planned enrollment of 100 is close to the median of 100 across 53 observational studies indexed under Polyneuropathies.

Browse Polyneuropathies studies →

Lead sponsor

University of Aarhus is the lead sponsor of 1,300 studies on the registry; 189 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with definite polyneuropathy (confirmed by nerve conductions study) diagnosed in Jutland, Denmark and orthostatic hypotension or non-nocturnal blood pressure reduction.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Definite polyneuropathy without known etiology (idiopathic) AND orthostatic hypotension (active stand test) OR non-nocturnal blood pressure reduction (24 hour blood pressure measurement)

Exclusion criteria

Exclusion Criteria:

  • Known etiology of polyneuropathy
  • A diagnosis of either dementia, Parkinson's disease, Dementia with Lewy Bodies or Multiple System Atrophy.
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Idiopathic polyneuropathy with abnormal cardiac 123I-MIBG scintigraphy

    Participants diagnosed with polyneuropathy, orthostatic hypotension or non-nocturnal blood pressure dip and abnormal cardiac 123I-MIBG scintigraphy (cardiac sympathetic dysfunction)

  • Idiopathic polyneuropathy with normal cardiac 123I-MIBG scintigraphy

    Participants diagnosed with polyneuropathy, orthostatic hypotension or non-nocturnal blood pressure dip and normal cardiac 123I-MIBG scintigraphy

06

What researchers measure

Primary outcomes

  1. Number of participants with REM sleep behavior disorder (RBD)

    RBD-status will be assessed by one-night video-polysomnography and REM Sleep Behavior Disorder Screening questionnaire (RBDSQ). Diagnosis of RBD according to American Academy of Sleep Medicine (AASM) criteria.

    Time frame: RBD-status is assessed at two time point: Baseline (at the time of enrollment) and 5-year follow-up

Secondary outcomes

  1. Number of participants with Parkinson's Disease (PD) or related alpha-synucleinopathies (Dementia with Lewy bodies (DLB), Multiple System atrophy (MSA)), REM-Sleep without atonia (RSWA)

    Diagnosis of Parkinson's Disease according to Movement Disorder Society (MDS) Clinical Diagnostic Criteria (Postuma et al., 2015) supported by dopamine transporter imaging (18F-PE2I-PET). Diagnosis of Dementia with Lewy bodies according to the Dementia with Lewy Bodies Consortium (Mckeith et al., 2017) Diagnosis of Multiple System Atrophy according to MDS Clinical Diagnostic Criteria (Whenning et al., 2022) REM-sleep without atonia (RSWA) is assessed by one-night video-polysomnography

    Time frame: Assessed at baseline (at the time of enrollment) and at 5-year follow-up

07

Study locations

1 site
  • Institute of Clinical Medicine, Aarhus University
    Aarhus, Jutland 8200, Denmark
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for May 2031, 83 months after the start.

Of 26 observational studies under Polyneuropathies, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 93. This study's planned 83 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2024
First posted
Dec 20, 2024
StartActual
May 13, 2024
Primary completionEst.
May 1, 2031
CompletionEst.
May 1, 2031
Last update
Jan 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06745011
Responsible party
Sponsor
First posted
Dec 20, 2024
Start date
May 13, 2024
Primary completion
May 1, 2031 (estimated)
Completion
May 1, 2031 (estimated)
Last update
Jan 8, 2025

Study contacts

Astrid J. Terkelsen, MD, DrMedSc, PhD, Professor
principal investigator · Department of clinical medicine, Aarhus University and Department of Neurology, Aarhus University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion